#gene therapy #無し #Market Insights #Hemophilia A

Forecasts Show Hemophilia A Market Growth Driven by New Treatments and Rising Cases

Growth of the Hemophilia A Market

The hemophilia A market is projected to exhibit a steady growth rate of 2.9% CAGR between 2025 and 2034. This upward trend is anticipated due to several key factors, including a rising prevalence of hemophilia, an increase in the availability of new treatment options, and the emergence of costly gene therapies.

Current Landscape

According to a recent report by DelveInsight, the market size for hemophilia A in major regions like the United States, EU4 countries, United Kingdom, and Japan reached USD 12.2 billion in 2024. The United States holds a significant share, contributing about 48% of the total market. Notably, the total diagnosed cases in these regions stood at approximately 49,500 in 2024, indicating a growing patient population that requires ongoing care.

Market Drivers

Increasing Patient Pool

One of the primary drivers of growth in the hemophilia A market is the increasing number of diagnosed cases. With advancements in diagnostic technologies and growing awareness of the disease, the number of individuals diagnosed with hemophilia A is expected to rise to 50,000 by 2034. This surge in patient numbers can lead to a higher demand for treatments, thereby expanding the market further.

Advances in Gene Therapy

Recent advancements in gene therapy have introduced transformational treatment approaches for hemophilia A. Among the forefront is BioMarin's ROCTAVIAN, which has already gained approval in both the U.S. and EU. This innovative therapy offers patients a long-lasting solution with a single infusion that targets the underlying factor VIII deficiency. Additionally, Pfizer's gene therapy, giroctocogene fitelparvovec, shows promising results in clinical trials, with significant reductions in bleeding episodes compared to traditional therapies.

Regulatory Support and Product Innovation

Recent regulatory approvals from the U.S. FDA have further bolstered the market. Newly approved drugs like Pfizer's HYMPAVZI and Sanofi's QFITLIA have broadened the options available for hemophilia A patients, particularly those aged 12 and over. These drugs aim to prevent or reduce bleeding episodes, signifying a shift towards more effective treatment strategies.

Non-Factor Therapies

The emergence of non-factor therapies is another noteworthy trend reshaping the hemophilia A market. These innovative treatments, such as anti-TFPI therapies and siRNA therapies, like HYMPAVZI and QFITLIA, are shifting the focus away from traditional factor replacement therapies to more sustainable options that provide enhanced patient outcomes.

Clinical Trials Surge

The clinical trial landscape is bustling with activities, as multiple pharmaceutical companies, including Novo Nordisk, Sangamo Therapeutics, and Roche, are pushing their pipeline therapies towards the market. Notable emerging therapies include Mim8, DTX201, and giroctocogene fitelparvovec, among others, which promise to reshape treatment paradigms for hemophilia A.